Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

Persistence of high-grade prostatic intra-epithelial neoplasia under combined androgen blockade therapy.

van der Kwast TH, Labrie F, Tetu B.

Hum Pathol. 1999 Dec;30(12):1503-7.

PMID:
10667430
2.

Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients.

Civantos F, Marcial MA, Banks ER, Ho CK, Speights VO, Drew PA, Murphy WM, Soloway MS.

Cancer. 1995 Apr 1;75(7):1634-41.

3.

Androgen receptors in untreated and treated prostatic intraepithelial neoplasia.

van der Kwast TH, Têtu B.

Eur Urol. 1996;30(2):265-8.

PMID:
8875210
4.

Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients.

Mazzucchelli R, Montironi R, Santinelli A, Lucarini G, Pugnaloni A, Biagini G.

Prostate. 2000 Sep 15;45(1):72-9.

PMID:
10960845
5.
6.

Functional heterogeneity of prostatic intraepithelial neoplasia: the duration of hormonal therapy influences the response.

Kang TY, Nichols P, Skinner E, Groshen S, Valin G, Ye W, Raghavan D.

BJU Int. 2007 May;99(5):1024-7. Epub 2007 Jan 22.

8.
9.

Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues.

Chang SS, Reuter VE, Heston WD, Hutchinson B, Grauer LS, Gaudin PB.

Cancer. 2000 Jan 15;88(2):407-15.

PMID:
10640975
10.

Intermediate biomarkers for chemoprevention of prostate cancer.

van der Kwast TH.

IARC Sci Publ. 2001;154:199-205. Review.

PMID:
11220659
11.

Effect of neoadjuvant hormonal therapy on prostatic intraepithelial neoplasia and its prognostic significance.

Balaji KC, Rabbani F, Tsai H, Bastar A, Fair WR.

J Urol. 1999 Sep;162(3 Pt 1):753-7.

PMID:
10458359
12.

High-grade prostatic intraepithelial neoplasialike ductal adenocarcinoma of the prostate: a clinicopathologic study of 28 cases.

Tavora F, Epstein JI.

Am J Surg Pathol. 2008 Jul;32(7):1060-7. doi: 10.1097/PAS.0b013e318160edaf.

PMID:
18496142
13.

Adjuvant hormonotherapy in patients with clinically-localized prostate cancer treated by radical prostatectomy: pathological results.

Têtu B.

Can J Oncol. 1994 Nov;4 Suppl 1:33-4; discussion 35-6. No abstract available.

PMID:
8853487
14.

Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study.

Vailancourt L, Ttu B, Fradet Y, Dupont A, Gomez J, Cusan L, Suburu ER, Diamond P, Candas B, Labrie F.

Am J Surg Pathol. 1996 Jan;20(1):86-93.

PMID:
8540613
15.
16.

Histopathological effects of androgen deprivation in prostatic cancer.

Civantos F, Soloway MS, Pinto JE.

Semin Urol Oncol. 1996 May;14(2 Suppl 2):22-31.

PMID:
8725888
18.

Apoptotic bodies in prostatic intraepithelial neoplasia and prostatic adenocarcinoma following total androgen ablation.

Montironi R, Magi-Galluzzi C, Fabris G.

Pathol Res Pract. 1995 Sep;191(9):873-80.

PMID:
8606868
19.

Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapy.

van der Kwast TH, Têtu B, Candas B, Gomez JL, Cusan L, Labrie F.

Urology. 1999 Mar;53(3):523-9.

PMID:
10096378
20.

Supplemental Content

Support Center